Vivesto AB (VIVE.ST)
SEK 0.27
(-1.45%)
SEK 0.27
(-1.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -356.71 Million SEK | -177.29% |
| 2021 | -128.64 Million SEK | -327.6% |
| 2020 | -30.08 Million SEK | 0.0% |
| 2019 | -30.08 Million SEK | 74.96% |
| 2018 | -120.13 Million SEK | -15.82% |
| 2017 | -103.72 Million SEK | 26.17% |
| 2016 | -140.48 Million SEK | -5.87% |
| 2015 | -132.69 Million SEK | -22.61% |
| 2014 | -108.22 Million SEK | -10.33% |
| 2013 | -98.09 Million SEK | -45.14% |
| 2012 | -67.58 Million SEK | -3.12% |
| 2011 | -65.53 Million SEK | -1.84% |
| 2010 | -64.35 Million SEK | -330.14% |
| 2009 | -14.96 Million SEK | -109.07% |
| 2008 | -7.15 Million SEK | -47.39% |
| 2007 | -4.85 Million SEK | 48.36% |
| 2006 | -9.4 Million SEK | -36.03% |
| 2005 | -6.91 Million SEK | -107.63% |
| 2004 | -3.32 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -21.53 Million SEK | 90.33% |
| 2023 Q2 | -28.84 Million SEK | -33.92% |
| 2022 Q3 | -71.37 Million SEK | -96.49% |
| 2022 FY | -356.71 Million SEK | -177.29% |
| 2022 Q1 | -26.32 Million SEK | -1173.16% |
| 2022 Q2 | -36.32 Million SEK | -37.96% |
| 2022 Q4 | -222.74 Million SEK | -212.1% |
| 2021 Q1 | -40.84 Million SEK | 79.31% |
| 2021 Q4 | -2.06 Million SEK | 93.01% |
| 2021 Q2 | -56.16 Million SEK | -37.52% |
| 2021 Q3 | -29.57 Million SEK | 47.35% |
| 2021 FY | -128.64 Million SEK | -327.6% |
| 2020 Q1 | 111.11 Million SEK | 292.54% |
| 2020 Q2 | -49.22 Million SEK | -144.3% |
| 2020 Q3 | -53.69 Million SEK | -9.09% |
| 2020 Q4 | -197.36 Million SEK | -267.59% |
| 2020 FY | -30.08 Million SEK | 0.0% |
| 2019 Q1 | -44.5 Million SEK | -68.4% |
| 2019 Q4 | -57.7 Million SEK | -21.28% |
| 2019 FY | -30.08 Million SEK | 74.96% |
| 2019 Q3 | -47.58 Million SEK | -32.5% |
| 2019 Q2 | -35.9 Million SEK | 19.32% |
| 2018 Q2 | -26.57 Million SEK | 5.16% |
| 2018 FY | -120.13 Million SEK | -15.82% |
| 2018 Q4 | -26.42 Million SEK | -16.8% |
| 2018 Q1 | -28.01 Million SEK | -11.36% |
| 2018 Q3 | -22.62 Million SEK | 14.85% |
| 2017 Q2 | -28.42 Million SEK | 24.03% |
| 2017 Q4 | -25.15 Million SEK | -13.69% |
| 2017 FY | -103.72 Million SEK | 26.17% |
| 2017 Q3 | -22.12 Million SEK | 22.14% |
| 2017 Q1 | -37.41 Million SEK | -7.31% |
| 2016 FY | -140.48 Million SEK | -5.87% |
| 2016 Q1 | -30.61 Million SEK | -31.72% |
| 2016 Q4 | -34.86 Million SEK | 2.8% |
| 2016 Q3 | -35.86 Million SEK | -10.9% |
| 2016 Q2 | -32.34 Million SEK | -5.63% |
| 2015 Q1 | -28.25 Million SEK | -10.88% |
| 2015 Q4 | -23.24 Million SEK | 43.32% |
| 2015 Q2 | -37.81 Million SEK | -33.87% |
| 2015 Q3 | -41 Million SEK | -8.43% |
| 2015 FY | -132.69 Million SEK | -22.61% |
| 2014 Q2 | -30.35 Million SEK | 13.87% |
| 2014 Q3 | -24.14 Million SEK | 20.45% |
| 2014 Q4 | -25.47 Million SEK | -5.52% |
| 2014 Q1 | -35.24 Million SEK | -23.68% |
| 2014 FY | -108.22 Million SEK | -10.33% |
| 2013 Q4 | -28.49 Million SEK | -63.99% |
| 2013 Q3 | -17.37 Million SEK | -2.29% |
| 2013 Q2 | -16.98 Million SEK | 22.51% |
| 2013 Q1 | -21.91 Million SEK | -52.2% |
| 2013 FY | -98.09 Million SEK | -45.14% |
| 2012 Q3 | -12.93 Million SEK | -170.57% |
| 2012 Q4 | -14.4 Million SEK | -11.34% |
| 2012 FY | -67.58 Million SEK | -3.12% |
| 2012 Q1 | -19.41 Million SEK | -11.83% |
| 2012 Q2 | 18.32 Million SEK | 194.39% |
| 2011 Q4 | -17.36 Million SEK | -1070.94% |
| 2011 FY | -65.53 Million SEK | -1.84% |
| 2011 Q1 | -21.76 Million SEK | -40.03% |
| 2011 Q2 | -15.36 Million SEK | 29.39% |
| 2011 Q3 | -1.48 Million SEK | 90.35% |
| 2010 Q2 | -11.21 Million SEK | -116.23% |
| 2010 Q3 | -15.83 Million SEK | -41.16% |
| 2010 Q4 | -15.54 Million SEK | 1.84% |
| 2010 FY | -64.35 Million SEK | -330.14% |
| 2010 Q1 | -5.18 Million SEK | 55.59% |
| 2009 Q4 | -11.67 Million SEK | -33.95% |
| 2009 Q2 | 10.62 Million SEK | 0.0% |
| 2009 Q3 | -8.71 Million SEK | -182.07% |
| 2009 FY | -14.96 Million SEK | -109.07% |
| 2008 FY | -7.15 Million SEK | -47.39% |
| 2007 FY | -4.85 Million SEK | 48.36% |
| 2006 FY | -9.4 Million SEK | -36.03% |
| 2005 FY | -6.91 Million SEK | -107.63% |
| 2004 FY | -3.32 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -2592.422% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | -832.306% |
| BioGaia AB (publ) | 440.9 Million SEK | 180.905% |
| Enzymatica AB (publ) | -48.06 Million SEK | -642.206% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | -752.62% |
| Gabather AB (publ) | -9.47 Million SEK | -3665.242% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | -2329.966% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | -1198.908% |
| Nanexa AB (publ) | -76.62 Million SEK | -365.539% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | -2433.876% |
| ODI Pharma AB | -1.34 Million SEK | -26488.28% |
| Orexo AB (publ) | -109.5 Million SEK | -225.771% |
| Probi AB (publ) | 11.32 Million SEK | 3251.228% |
| Swedencare AB (publ) | 173.2 Million SEK | 305.958% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 107.661% |
| Toleranzia AB | -7.89 Million SEK | -4420.58% |